Sintilimab plus GemOx is an effective salvage therapy in patients with refractory/relapsing nodal peripheral T cell lymphomas.
Humans
Male
Female
Salvage Therapy
/ methods
Middle Aged
Lymphoma, T-Cell, Peripheral
/ drug therapy
Antibodies, Monoclonal, Humanized
/ administration & dosage
Retrospective Studies
Adult
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Aged
Gemcitabine
Deoxycytidine
/ analogs & derivatives
Oxaliplatin
/ administration & dosage
Neoplasm Recurrence, Local
/ drug therapy
Young Adult
Organoplatinum Compounds
Chemoimmunotherapy
GemOx
PTCL
Salvage therapy
Sintilimab
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
06
08
2024
accepted:
13
09
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
epublish
Résumé
The retrospective study was to explore the effectiveness and safety of GemOx (gemcitabine, oxaliplatin) plus sintilimab (belongs to the class of drugs known as immune checkpoint inhibitors, particularly targeting the PD-1 receptor) in relapse or refractory nodal PTCLs. Patients with nodal PTCL who initiated salvage therapy with sintilimab and GemOx between January 2020 to September 2021 were identified from the database of the hematology department of the Second Affiliated Hospital of Zhejiang University School of Medicine. All patients received 2-4 cycles (3 weeks/cycle) of treatment of sintilimab (200 mg, I.V, D1) in combination with GemOx. Treatment response was assessed every six weeks during the salvage treatment phase. Eligible patients received maintenance therapy according to the investigator's decision. Follow-ups were routinely conducted every three months. 31 patients with r/r nodal PTCLs were enrolled, including 23 PTCL-NOS, 4 AITL, and 4 ALCL. 21 (67.7%) patients received at least two lines of therapy. 71.0% (95% CI, 53.4%-83.9%) of patients documented objective response of 2-4 cycles of sintilimab plus GemOx therapy, including 9 complete response and 13 partial response. 21 (67.7%) patients received consolidation therapy, including 5 autologous stem-cell transplantation and 12 histone deacetylase inhibitors. After a median 25.6 months follow-up, the median PFS was 22.0 (95% CI,11.8-24.7) months, and the median OS was 26.2 (95% CI, 24.4 -NA) months. 29 (93.5%) patients experienced at least one adverse event, and 26 (83.9% patients only had mild (grade 1-2) AEs.Univariable Cox regression showed the progression risk of AITL is 22.7 (3.9- 131.0, p < 0.01) times of PTCL-NOS, while the HR of ALCL was 1.14 (0.33-3.96,p = 0.833). Sintilimab plus GemOx showed encouraging activity and manageable toxicity for patients with r/r PTCL.
Identifiants
pubmed: 39299973
doi: 10.1007/s00432-024-05956-3
pii: 10.1007/s00432-024-05956-3
doi:
Substances chimiques
sintilimab
8FU7FQ8UPK
Antibodies, Monoclonal, Humanized
0
Gemcitabine
0
Deoxycytidine
0W860991D6
Oxaliplatin
04ZR38536J
Organoplatinum Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
425Informations de copyright
© 2024. The Author(s).
Références
Barta SK, Zain J, MacFarlane AT et al (2019) Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma[J]. Clin Lymphoma Myeloma Leuk 19(6):356–364. https://doi.org/10.1016/j.clml.2019.03.022
doi: 10.1016/j.clml.2019.03.022
pubmed: 31029646
pmcid: 7433797
Bennani NN, Pederson LD, Atherton P et al (2019) A Phase II study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma[J]. Blood 134(1):467
doi: 10.1182/blood-2019-126194
Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800
doi: 10.1200/JCO.2013.54.8800
pubmed: 25113753
pmcid: 4979083
Ellin F, Landstrom J, Jerkeman M et al (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry[J]. Blood 124(10):1570–1577. https://doi.org/10.1182/blood-2014-04-573089
doi: 10.1182/blood-2014-04-573089
pubmed: 25006130
Fiore D, Cappelli LV, Broccoli A et al (2020) Peripheral T cell lymphomas: from the bench to the clinic[J]. Nat Rev Cancer 20(6):323–342. https://doi.org/10.1038/s41568-020-0247-0
doi: 10.1038/s41568-020-0247-0
pubmed: 32249838
Garcia-Sancho AM, Bellei M, Lopez-Parra M et al (2022) Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study[J]. Haematologica 107(11):2675–2684. https://doi.org/10.3324/haematol.2021.279426
doi: 10.3324/haematol.2021.279426
pubmed: 35320921
pmcid: 9614542
Lu Z, Wang J, Shu Y et al (2022) Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ 377:e68714. https://doi.org/10.1136/bmj-2021-068714
doi: 10.1136/bmj-2021-068714
Miyoshi H, Kiyasu J, Kato T et al (2016) PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma[J]. Blood 128(10):1374–1381. https://doi.org/10.1182/blood-2016-02-698936
doi: 10.1182/blood-2016-02-698936
pubmed: 27418641
Shen H, Ji Y, Zhou D et al (2019) Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis[J]. Hematology 24(1):392–398. https://doi.org/10.1080/16078454.2019.1590965
doi: 10.1080/16078454.2019.1590965
pubmed: 30890046
Shi Y, Dong M, Hong X et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J]. Ann Oncol 26(8):1766–1771. https://doi.org/10.1093/annonc/mdv237
doi: 10.1093/annonc/mdv237
pubmed: 26105599
Shi Y, Wu J, Wang Z et al (2021) Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)[J]. J Hematol Oncol 14(1):12. https://doi.org/10.1186/s13045-021-01033-1
doi: 10.1186/s13045-021-01033-1
pubmed: 33436023
pmcid: 7802130
Sibon D (2022) Peripheral T-cell lymphomas: therapeutic approaches[J]. Cancers 14(9):2332
doi: 10.3390/cancers14092332
pubmed: 35565460
pmcid: 9104854
Smith SM, Burns LJ, van Besien K et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma[J]. J Clin Oncol 31(25):3100–3109. https://doi.org/10.1200/JCO.2012.46.0188
doi: 10.1200/JCO.2012.46.0188
pubmed: 23897963
pmcid: 3753702
Sun J, Yang Q, Lu Z et al (2012) Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification[J]. Am J Clin Pathol 138(3):429–434. https://doi.org/10.1309/AJCP7YLTQPUSDQ5C
doi: 10.1309/AJCP7YLTQPUSDQ5C
pubmed: 22912361
Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569
doi: 10.1182/blood-2016-01-643569
pubmed: 26980727
pmcid: 4874220
Tao R, Fan L, Song Y et al (2021) Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)[J]. Signal Transduct Target Ther 6(1):365. https://doi.org/10.1038/s41392-021-00768-0
doi: 10.1038/s41392-021-00768-0
pubmed: 34702811
pmcid: 8548511
Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol 26(25):4124–4130. https://doi.org/10.1200/JCO.2008.16.4558
doi: 10.1200/JCO.2008.16.4558
pubmed: 18626005
Yang Y, Sun J, Wang Z et al (2021) Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study[J]. J Thorac Oncol 16(12):2109–2120. https://doi.org/10.1016/j.jtho.2021.07.015
doi: 10.1016/j.jtho.2021.07.015
pubmed: 34358724